Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ACELYRIN, INC. - Common Stock (NQ: SLRN )

2.600 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACELYRIN, INC. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
ROSEN, NATIONAL TRIAL LAWYERS, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
WHY: NEW YORK, NY - (NewMediaWire) - November 25, 2023 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ACELYRIN, INC. (NYSE: SLRN) between May 4, 2023 and... 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
SLRN NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of ACELYRIN, Inc. (SLRN) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
NASDAQ:SLRN Investor Notice: Investigation over Potential Wrongdoing at Acelyrin, Inc.
San Diego, CA -- (SBWIRE) -- 10/31/2023 -- Certain directors of Acelyrin, Inc. are under investigation over potential breaches of fiduciary duties. 
Via SBWire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ACELYRIN, Inc. (SLRN) Investors
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, LEADING INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLRN
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm PA
Via GlobeNewswire
Acelyrin, Inc. (SLRN) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Acelyrin, Inc.
From Robbins LLP
Via Business Wire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages ACELYRIN, INC. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLRN
From The Rosen Law Firm, P.A.
Via Business Wire
SLRN INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Acelyrin, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Acelyrin (SLRN) Q3 2023 Earnings Call Transcript
SLRN earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
From ACELYRIN, INC.
Via GlobeNewswire
ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer
From Acelyrin, Inc.
Via GlobeNewswire
ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023
From Acelyrin, Inc.
Via GlobeNewswire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Acelyrin, Inc. (SLRN) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
NASDAQ:SLRN Shareholder Notice: Investigation over Possible Securities Laws Violations by Acelyrin, Inc.
San Diego, CA -- (SBWIRE) -- 10/06/2023 -- An investigation was announced over potential securities laws violations by Acelyrin, Inc in connection with certain financial statements. 
Via SBWire
ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development
From Acelyrin, Inc.
Via GlobeNewswire
Moonshot Medicine: 3 Stocks to Buy to Bet on Long-Shot Drugs
The best drug stocks to buy now are shooting for the moon. These three trailblazers will land among the stars. 
Via InvestorPlace
ACELYRIN ALERT: Bragar Eagel & Squire, P.C. is Investigating Acelyrin, Inc. on Behalf of Acelyrin Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
  During the session on Thursday, 461 stocks hit new 52-week lows. 
Via Benzinga
Why Acelyrin Stock Plummeted 59% This Week
The recently public biopharma company announced disappointing results from a clinical trial of its lead drug candidate. 
Via The Motley Fool
Why Eiger BioPharmaceuticals Shares Are Trading Lower By 52%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Avalo Therapeutics, Inc. (NASDAQ: AVTX) shares surged 68% to $0.2075. Avalo Therapeutics, on Sept 12, got notice from the Nasdaq as of Sept 11 the company’s securities had closing bid price of... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.